Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Financial Results, New Appointments, and Stock Price Movements - Research Report on Salix Pharmaceuticals, Cigna, St. Jude



  Financial Results, New Appointments, and Stock Price Movements - Research
    Report on Salix Pharmaceuticals, Cigna, St. Jude Medical, Zimmer, and
                                  CareFusion

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 13, 2013

NEW YORK, November 13, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Salix
Pharmaceuticals, Ltd. (NASDAQ: SLXP), Cigna Corporation (NYSE: CI), St. Jude
Medical, Inc. (NYSE: STJ), Zimmer Holdings, Inc. (NYSE: ZMH), and CareFusion
Corporation (NYSE: CFN). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Salix Pharmaceuticals, Ltd. Research Report

On November 7, 2013, Salix Pharmaceuticals, Ltd. (Salix Pharmaceuticals)
announced its Q3 2013 financial results. The Company's net product revenues
increased 28.7% YoY to $238.2 million during the quarter. Net income was $47.3
million or $0.71 per diluted share in Q3 2013, compared to net income of $16.5
million or $0.26 per diluted share in Q3 2012. Commenting on the results,
Carolyn Logan, President and CEO of Salix Pharmaceuticals, said, "XIFAXAN 550
for the treatment of hepatic encephalopathy continues to demonstrate sustained
growth and market penetration. During 10 weeks of the past 12 weeks XIFAXAN
550 achieved a record-high level of total prescriptions." Logan added, "Salix
continues to succeed in our mission of being the leading specialty
pharmaceutical company licensing, developing and marketing innovative products
to healthcare professionals to prevent or treat gastrointestinal disorders. We
believe our acquisition of Santarus and the combined assets of our two
companies should create a larger, even stronger Salix that will be better
positioned to provide solutions for gastrointestinal disorders to patients and
healthcare providers." The Full Research Report on Salix Pharmaceuticals, Ltd.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/04fa_SLXP]

--

Cigna Corporation Research Report

On November 7, 2013, Cigna Corporation (Cigna) announced that the Company
named Edward Kim as President and General Manager for the Company's Arizona
health plans, along with his current role as President of Cigna Medical Group.
According to Cigna, Kim's additional responsibilities include enhancing
customer satisfaction through personalized service and helping to improve
quality of care by working in collaboration with area health care
professionals. Cigna added that his new responsibilities also include ensuring
that the Company's product and network offerings meet the evolving needs of
the marketplace, assisting employer clients to improve the health and
productivity of their workforces, and leading its efforts to serve the
community. The Full Research Report on Cigna Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7307_CI]

--

St. Jude Medical, Inc. Research Report

On November 8, 2013, St. Jude Medical, Inc.'s (St. Jude Medical) stock rose
1.37%, ending the day at $56.99. Over the previous three trading sessions,
shares of St. Jude Medical declined 0.94% compared to the S&P 500 which gained
0.43% during the same period. The Full Research Report on St. Jude Medical,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b338_STJ]

--

Zimmer Holdings, Inc. Research Report

On November 8, 2013, Zimmer Holdings, Inc.'s (Zimmer) stock rose 0.26%, ending
the day at $88.59. Over the previous three trading sessions, shares of Zimmer
declined 0.39% compared to the S&P 500 which gained 0.43% during the same
period. The Full Research Report on Zimmer Holdings, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9db9_ZMH]

--

CareFusion Corporation Research Report

On November 7, 2013, CareFusion Corporation (CareFusion) reported its Q1 FY
2014 financial results (period ended September 30, 2013). The Company's
revenue declined 0.8% YoY to $830 million during the quarter. Net income was
$78 million or $0.36 per diluted share in Q1 FY 2014, compared to net income
of $84 or $0.37 per diluted share in Q1 FY 2013. Commenting on the results,
Kieran T. Gallahue, Chairman and CEO of CareFusion, said, "Our team executed
well and delivered solid first quarter results, putting us on the right track
for the full fiscal year. I'm pleased with the way our Procedural Solutions
team continues to perform across the board, and, with good visibility into our
capital business, we continue to anticipate a strong second half of the year
in Medical Systems." Gallahue added, "During the quarter, we continued to make
strategic progress, closing our Sendal acquisition in Spain as part of our
strategy to globalize the company and ramping up our R&D investments in the
Procedural Solutions segment as we prepare to launch several new products over
the next 18 months." The Full Research Report on CareFusion Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4933_CFN]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement